<DOC>
	<DOCNO>NCT02015156</DOCNO>
	<brief_summary>This study prove difference number healthy male volunteer experience pyrexia ( i.e . fever body temperature 38Â°C high ) within 24 hour period administration single dose 6mg/kg PF-05280014 trastuzumab source United States ( trastuzumab-US ) . The study also compare safety drug .</brief_summary>
	<brief_title>A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers ( REFLECTIONS B327-06 )</brief_title>
	<detailed_description>Safety evaluation .</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg^m2 ; total body weight &gt; 50 kg ( 110 lb ) . Left ventricular ejection fraction ( LVEF ) within normal range measure echocardiogram ( ECHO ) within 8 week prior randomization . Subjects previously expose biologic agent ( HER2 inhibitor ) may enroll provide least 3 month pass since last administration drug . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Previous exposure antiHER2 antibody . History serious allergic anaphylactic reaction therapeutic drug benzyl alcohol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Trastuzumab</keyword>
	<keyword>Healthy Male Volunteers</keyword>
	<keyword>Single-Dose</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Biosimilarity</keyword>
</DOC>